Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel
Case Report
Tumor Necrosis in a Breast Cancer Case as a Result of a Novel Systemic Magnetic Nanoparticle Hyperthermia "Firstin-Human" Safety and Feasibility Trial
Author(s): Sarah Kraus*, Boaz Shalev, Shir Arbib, Pazit Rukenstein, Moshe Eltanani, Udi Ron, Shaul Atar and Ofer Shalev
Background: We report a case of a patient with metastatic breast cancer that was treated with a novel magnetic nanoparticle hyperthermia approach for the treatment of solid tumors comprising of systemic administration of iron oxide multicore encapsulated nanoparticles, named Sarah Nanoparticles (SaNPs), and Alternating Magnetic Field (AMF) irradiation.
Case description: The patient participated in an ongoing open label feasibility ascending dose study designed to evaluate patients with stage IV solid tumors. The primary objective of the trial was to assess the safety profile of the approach. Eligibility criteria included patients with a life expectancy of at least 30 days, histologically confirmed advanced metastatic solid tumors that have progressed on or after standard therapy. Toxicity was evaluated using standard criteria for the grading.. Read More»
DOI:
10.37421/2165-7920.2024.14.1596
Journal of Clinical Case Reports received 1345 citations as per Google Scholar report